Bianco Files 13D for TuHURA Biosciences

TL;DR

CEO Bianco filed a 13D for TuHURA (fka Kintara) - ownership update.

AI Summary

James A. Bianco, President and CEO of TuHURA Biosciences, Inc., filed a Schedule 13D on October 25, 2024, indicating his beneficial ownership of the company's common stock. The filing details changes in his holdings and intentions regarding the company, which was formerly known as Kintara Therapeutics, Inc. Bianco's address is listed as 10500 University Center Drive, Suite 110, Tampa, FL 33612.

Why It Matters

This filing provides insight into the ownership and potential strategic direction of TuHURA Biosciences from its CEO, which can influence investor decisions.

Risk Assessment

Risk Level: medium — Schedule 13D filings can signal significant changes in control or strategy, warranting investor attention.

Key Players & Entities

• James A. Bianco (person) — Filer, President and CEO of TuHURA Biosciences, Inc.
• TuHURA Biosciences, Inc. (company) — Subject Company
• Kintara Therapeutics, Inc. (company) — Former name of TuHURA Biosciences, Inc.
• DelMar Pharmaceuticals, Inc. (company) — Former name of TuHURA Biosciences, Inc.
• Berry Only Inc. (company) — Former name of TuHURA Biosciences, Inc.
• 0000897069-24-002046 (filing_id) — Accession Number for the filing

FAQ

Key Financial Figures

• $0.001 — ame of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securitie

Filing Documents

• bianco13d.htm (SC 13D) — 29KB
• 0000897069-24-002046.txt ( ) — 31KB

SECURITY AND ISSUER

ITEM 1. SECURITY AND ISSUER This statement on Schedule 13D relates to the common stock, par value $0.001 per share (the "Common Stock"), of TuHURA Biosciences, Inc., a Nevada corporation (the "Issuer"). The principal executive offices of the Issuer are located at 10500 University Drive, Suite 110, Tampa, Florida 33612. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.

IDENTITY AND BACKGROUND

ITEM 2. IDENTITY AND BACKGROUND This Schedule 13D is being filed by James A. Bianco, M.D. (the "Reporting Person"). The address of the Reporting Person is c/o TuHURA Biosciences, Inc., 10500 University Drive, Suite 110, Tampa, Florida 33612. The Reporting Person is the President and Chief Executive Officer and a director of the Issuer and is a citizen of the United States of America. During the last five years, the Reporting Person has not been: (i) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors); or (ii) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION

ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION On April 2, 2024, Kintara Therapeutics, Inc. ("Kintara"), Kayak Mergeco, Inc., a wholly-owned subsidiary of Kintara incorporated in the State of Delaware ("Merger Sub"), and TuHURA Biosciences, Inc. ("TuHURA") entered into an Agreement and Plan of Merger (the "Merger Agreement"), which, among other things, provided for Merger Sub to merge with and into TuHURA, with TuHURA surviving as a direct wholly-owned subsidiary of Kintara and the surviving corporation (the "Business Combination"). On October 18, 2024, the parties to the Merger Agreement consummated the Business Combination in accordance with the Merger Agreement (the "Closing"). All references to "Kintara" refer to the Issuer prior to the Closing, and all references to TuHURA refer to TuHURA Biosciences, Inc. prior to the Closing. Immediately prior to the Closing, the Reporting Person held 12,986,622 shares of common stock of TuHURA. In the Business Combination, shares of TuHURA immediately prior to the Closing were converted into the right to receive shares of Common Stock at an exchange ratio of 0.1789 (after giving effect to a 1-for-35 reverse stock split of the shares of common stock of Kintara immediately prior to the Closing). At the Closing, the Reporting Person's shares were converted into 2,323,307 shares of Common Stock. 3

PURPOSE OF THE TRANSACTION

ITEM 4. PURPOSE OF THE TRANSACTION The Reporting Person acquired the securities described in this Schedule 13D in connection with the Closing. The Reporting Person is the President and Chief Executive Officer and a director of the Issuer. As a director of the Issuer, the Reporting Person may participate in discussions regarding every aspect of the Issuer's governance, management and operations, whether with management, other members of the Issuer's board of directors, investors, advisers and other persons. As the President and Chief Executive Officer of the Issuer, the Reporting Person has general supervision, direction and control of the business and officers of the Issuer. The Reporting Person may from time to time buy or sell securities of the Issuer as appropriate for his personal circumstances and reflecting his overall investment posture. Other than as described above and elsewhere in this Schedule 13D, the Reporting Person does not currently have any plans or proposals that relate to, or would result in, any of the matters listed in Items 4(a)–(j) of Schedule 13D, although the Reporting Person may change his purpose or formulate plans or proposals with respect thereto at any time.

INTEREST IN SECURITIES OF THE ISSUER

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER (a) As of the date hereof, the Reporting Person beneficially owned directly 2,704,901 shares of Common Stock, which represents 6.4% of the outstanding shares of Common Stock, which is comprised of (i) 2,323,307 shares of Common Stock, and (ii) 381,594 shares of Common Stock issuable upon the exercise of options held by the Reporting Person which are exercisable within 60 days of the date hereof. The percentage of ownership reported in this Item 5 was calculated in accordance with Rule 13d-3(d)(1)(i) promulgated under the Securities Exchange Act of 1934, as amended. (b) As of the date hereof, the Reporting Person has sole voting and dispositive power over 2,704,901 shares of Common Stock, which includes (i) 2,323,307 shares of Common Stock, and (ii) 381,594 shares of Common Stock issuable upon the exercise of options held by the Reporting Person which are exercisable within 60 days of the date hereof. (c) Except as described in Item 3, during the past 60 days the Reporting Person has not effected any transactions in the Common Stock. (d) None. (e) Not applicable.

CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER

ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER Concurrently and in connection with the execution of the Merger Agreement, certain Pre-Business Combination TuHURA executive officers, directors and stockholders as of immediately prior to the Business Combination, including the Reporting Person, entered into a lock-up agreement with the Issuer (the " Lock-up Agreements "), pursuant to which such parties agreed not to, except in limited circumstances, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock, currently or thereafter owned, until 180 days following the Closing of the Business Combination. The foregoing description of the Lock-up Agreements does not purport to be complete and is qualified in its entirety by reference to the form of the Lock-up Agreement, which is filed as Exhibit 10.2 to this Schedule 13D and incorporated herein by reference.

MATERIAL TO BE FILED AS EXHIBITS

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS Exhibit No. Description 10.1 10.2 Agreement and Plan of Merger, dated as of April 2, 2024, by and among Kintara Therapeutics, Inc., Kayak Mergeco, Inc., and TuHURA Biosciences, Inc. (incorporated by reference to Exhibit 2.1 of Kintara's Current Report on Form 8-K filed with the SEC on April 3, 2024). Form of Lock-up Agreement (incorporated by reference to Exhibit 10.3 of the Issuer's Current Report on Form 8-K filed with the SEC on April 3, 2024) . * Filed herewith. 4

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct. Dated: October 25, 2024 /s/ James A. Bianco Name: James A. Bianco, M.D. 5

View Full Filing

View this SC 13D filing on SEC EDGAR